Bringing Artificial Intelligence to physicians and researchers is what entrepreneur Eric Lefkofsky set out to do when he founded Tempus. The company’s developing technology uses AI/ Machine learning in a clinical data setting, which means more efficient and life-saving disease management. Under the leadership of Eric Lefkofksy, cancer, cardiology, and depression were a few of the fields Tempus had seen tremendous promise in, but then Covid hit.
Without sacrificing the company’s dedication to improve disease outcomes for their existing technology, Eric Lefkofsky turned his attention to new development – Infectious Disease. With an ample supply of cash infusion in this burgeoning market, the successful investor is bringing the power of Artificial Intelligence to the healthcare setting to make life better in the age of Covid. According to Eric Lefkofsky, Tempus will use this AI/ Machine Learning technology to improve upon ID Biomarkers in a clinical data setting, enabling physicians to make real-time, data-driven decisions to deliver personalized patient care.
With recent partnerships with Johnson and Johnson and ASCO and hundreds of millions in funding, Tempus has firm commitments in AI/ Machine learning technology. Eric Lefkofsky is continually looking into new technologies to improve people’s lives, including a new Tempus-driven Biomarker trial to give scientists better access to datasets for Glioblastoma patients. Tempus’s ultimate goal is to become the largest healthcare data center in the world.